Acorda Therapeutics Cost of Revenue 2011-2026 | ACOR

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Acorda Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
15.3 M	30.3 M	40.8 M	33.5 M	34.8 M	97.6 M	111 M	107 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
111 M	15.3 M	58.9 M

Quarterly Cost of Revenue Acorda Therapeutics

2024-Q1	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.71 M	3.23 M	-	11 M	8.8 M	5.97 M	-	13.3 M	11.3 M	12 M	-	12.2 M	6.66 M	3.84 M	-	7.99 M	9.4 M	8.8 M	-	25.2 M	30.4 M	20.6 M	-	30 M	29.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
30.4 M	3.23 M	13.4 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Nymox Pharmaceutical Corporation NYMX	4 K	-	-19.68 %	$ 18.4 M	Canada
Aptorum Group Limited APM	421 K	$ 0.9	-2.33 %	$ 6.62 M	China
ACADIA Pharmaceuticals ACAD	81.8 M	$ 21.96	-0.68 %	$ 3.64 B	USA
RedHill Biopharma Ltd. RDHL	49.4 M	$ 1.02	-0.49 %	$ 428 M	Israel
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	364 M	$ 21.41	1.9 %	$ 1 B	USA
AstraZeneca PLC AZN	12.4 B	-	-	$ 96.9 B	Britain
BioDelivery Sciences International BDSI	23.4 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	2.91 B	$ 105.46	-0.09 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
Aquestive Therapeutics AQST	18.6 M	$ 4.08	0.25 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	36.7 M	$ 23.26	1.75 %	$ 2.96 B	USA
Autolus Therapeutics plc AUTL	96.4 M	$ 1.44	-5.88 %	$ 383 M	Britain
BioXcel Therapeutics BTAI	164 K	$ 1.06	-3.64 %	$ 12.9 M	USA
CASI Pharmaceuticals CASI	12.6 M	-	-	$ 35.4 M	USA
bluebird bio BLUE	33.5 M	-	-	$ 546 M	USA